MONTHLY SUMMARY – AUGUST 2023

Summer doldrums! Following a five-month stretch of rising global stock prices, equity markets fell back slightly in August. After a better-than-feared earnings report season, investors re-focused on macro events. The tug-of-war in opinion regarding future central banks rate hikes, significantly higher yields on long-term government bonds, as well as worries over developments in the Chinese real-estate sector, all weighted down on risk willingness.

Tech stocks – the place to be in 2023 (so far)

As has been the case throughout 2023, information technology stocks were once again in focus in August. Following the very strong performance seen in the sector, earnings from bellwether chipmaker Nvidia, whose results were among the most anticipated, delivered yet another set of stellar numbers. After a minor consolidation, its shares continued to gain, confirming information technology as the place to be, so far this year.

Few surprises from Jackson Hole

The annual central bankers´ conference in Jackson Hole, Wyoming, delivered few surprises. Federal Reserve chairman, Jay Powell, stated that inflation was coming down but kept the door open for new hikes if warranted. Initially seen as hawkish by market participants, the statement was subsequently viewed as confirmation of the data-dependent stance communicated by the Fed for some time. Christine Lagarde, the head of the ECB, made some statements in her speech which were interpreted as slightly dovish, possibly against the backdrop of the bleak economic development in Europe, leaving a possible hike in September an open question. 

Several countries pledged further support to Ukraine

Ukraine´s counteroffensive seemed to have bogged down in August with few major breakthroughs. After a lengthy political process, Denmark, the Netherlands and Norway decided to supply Ukraine with US-made F-16 fighter jets, with training commencing shortly. Otherwise, attention was centered on the plane crash outside Moscow where the leaders of the Wagner mercenary group including figurehead Yevgeny Prigozhin were presumed killed. The crash, most likely caused by some kind of sabotage, was considered to have strengthened Vladimir Putin and the Russian regime.

The Chinese real estate sector back in focus

Apart from widespread disappointment over the lackluster growth in the Chinese economy so far this year, the real estate sector came under renewed scrutiny when the developer, Country Garden, failed to meet interest payments. Peer Evergrande had to seek chapter 15-protection in the US. The Chinese authorities responded by easing reserve ratios on banks, and also said they were prepared to cut duty tax on equity transactions in order to attract foreign investors to domestic financial markets.

A growing BRIC group

The BRIC group (Brazil, Russia, India and China) met in Johannesburg, South Africa, and decided to include a number of additional countries including Saudi Arabia, Iran and Egypt. The expansion was seen as an intention to challenge the Western world, not least as far as energy production is concerned.

World index down in August

The world index thus fell back slightly in August as measured in US dollars or Euros. Even though information technology and related sectors still lead performance tables by a wide margin so far in 2023 energy and healthcare outperformed the market in August, while utilities and financials lagged. Looking at the regions, the US outperformed Europe and Hong Kong declined the most.

 

OUTLOOK

At the beginning of August, almost everything struggled. It was particularly difficult for biotechnology and small caps, which continued to decline throughout the month. Despite reasonable earnings reports, medical technology and managed care had a surprisingly hard time. The pharmaceutical sector was the only sub-sector to properly bounce back from the initial decline, finishing on a reassuring plus.

Interest rates put pressure on the healthcare sector

The most important explanation for the weak development in the healthcare sector overall was the continued rise in interest rates, which for a while was significant, but which then fell back at the end of the month when inflation concerns subsided.

A September with an opportunity to surprise

Historically, September is a soft month, but has a good opportunity to surprise positively this year. Inflation continues to fall at the same time as many macro figures indicate good growth in the US and a continued good level of demand. The labor market is strong but no longer overheated to the same extent. Some analysts believe that final demand, and thus the economy, will decline during the fall when households’ reduced savings become evident. Time will tell.

Nevertheless, we believe that the opportunities for the sector outweigh the threats in this type of environment. The interest rate hikes should be over, and the economy may well have a soft landing. A minor recession in the US is still possible, and even likely in Europe. We believe the healthcare sector should fare better than many other sectors and we are more optimistic than usual for this time of year. Nevertheless, a certain amount of caution is, of course, both reasonable and appropriate.

 

Andra nyheter från oss

Alla

Direkt

Finwire

Okategoriserat

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

SV